Albireo Pharma Inc Stock News

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President

Mirum And Maralixibat In Pediatric Cholestasis: The Differentiation

– Bylvay is approved in the U.S. and EU as only once-daily drug indicated for patients with PFIC –

Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q2 2021 Results - Earnings Call Transcript

– Bylvay TM (odevixibat) approved in U.S. & EU as o nly once-daily drug indicated for patients with PFIC –

BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief

— Conference call and webcast to be held at 10:00 a.m. ET — — Conference call and webcast to be held at 10:00 a.m. ET —

Following FDA approval, Albireo's (ALBO) Bylvay becomes the first drug to treat pruritus in PFIC.

Just a day after European approval, Albireo Pharma Inc (NASDAQ: ALBO) has received FDA approval for Bylvay (odevixibat), the first drug approved to treat pruritus in all subtypes of progressive f

– Only once-daily drug indicated for the treatment of pruritus in PFIC –

– Only once-daily drug indicated for the treatment of pruritus in PFIC –

The European Commission (EC) has approved Albireo Pharma Inc's (NASDAQ: ALBO) Bylvay (odevixibat) for all subtypes of progressive familial intrahepatic cholestasis (PFIC).  Bylvay is a potent, non

– First approval in the world of Bylvay for the treatment of PFIC –

BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief

Albireo Pharma Inc (NASDAQ: ALBO) has announced pooled analysis from Phase 3 PEDFIC studies with Bylvay (odevixibat) and advancement in the characterization of A3907 in adult liver disease. Data wi